Document:

CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Exhibit 10.76

 

CONFIDENTIAL

 

Amendment
#1 

to
Collaboration AGREEMENT

 

THIS AMENDMENT #1
TO COLLABORATION AGREEMENT
(“First Amendment”) is made and entered into as of July 1, 2015 (the “First Amendment Effective Date”)
by and between Amyris, Inc., having its principal place of business located at 5885 Hollis St, Suite 100, Emeryville, CA
94608 USA (“Amyris”), and Firmenich SA, having its registered place of business at 1, route des Jeunes,
1208 Geneva Switzerland (“Firmenich”).

 

WHEREAS, Amyris
and Firmenich entered into that certain Collaboration Agreement on March 13, 2013 (the “Agreement”) to collaborate
on the development and worldwide use and commercialization of Ingredients in the F&F Market using Strain Generation Technology
Controlled by Amyris and other contributions of the Parties.

 

WHEREAS, pursuant
to the terms and conditions of this First Amendment, the Parties desire to amend the Agreement to update (i) funding milestones
and associated payments related to those milestones, (ii) the sharing of Profits and (iii) the calculation of a commercialization
bonus as set forth in Appendix F.

 

NOW THEREFORE,
in consideration of the promises and the mutual covenants contained herein, the Parties agree as follows:

 

		1.	Section 3.10.2 of the Agreement is hereby amended by deleting such section in its entirety and
replacing it with the following new section 3.10.2:

 

“3.10.2       In
addition, Firmenich will make the following four milestone payments to Amyris on the following conditions:

 

		•	Milestone 1: [*] within
thirty (30) days of achieving the Target Cost or less per kilogram of the Initial Ingredient meeting the Ingredient Specifications
when the Initial Ingredient is produced by Amyris (or on its behalf) in a “Qualifying Run” (i.e., in a [*]
fermenter or larger, at Amyris’ option); provided, that in determining
whether or not the Target Cost is achieved in such Qualifying Run, the Parties will use the agreed assumed costs of raw materials
and fermentation as set forth in the Target Cost Model, not the actual costs for such raw materials and fermentation incurred by
Amyris in such Qualifying Run.

 

		·	Milestone 2: [*] within
thirty (30) days of Amyris’s first delivery to Firmenich of at least [*] of
the Intermediate, [*], which amount is measured on a pure basis.
Payment for an achieved Milestone 2 will be made within thirty (30) days after agreement by the Steering Committee that this Milestone
2 has been achieved. Under this Milestone 2, the [*] shall be delivered
with a chemical purity of [*] and have a mass conversion yield
of [*] (on a pure basis) to [*] greater
than [*]. 

 

		·	Milestone 3: [*] if
Amyris delivers, prior to December 31, 2015, at least [*] of [*],
which amount is measured on a pure basis, that meets the requirements in this paragraph. Payment for an achieved Milestone 3 will
be made within thirty (30) days after agreement by the Steering Committee that this Milestone 3 has been achieved. To satisfy this
Milestone 3, (i) the 

 

[*] Certain
portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.

    
	CONFIDENTIAL	 Page 1 of 5	 

     

    

	 	·	[*] shall
have a chemical purity that meets the Ingredient Specifications, (ii) the [*] shall
have a mass conversion yield of the [*] (on a pure basis) to [*],
and (iii) the final [*] produced from such [*] must
meet an olfactive standard set by Firmenich. In the event Amyris fails to deliver the [*] described
herein prior to December 31, 2015, Amyris will still earn the Milestone 3 payment if it meets Milestone 3 no later than June 30,
2016, though the payment in that case will be [*].

 

		·	Milestone 4: [*] if
Amyris achieves the Target Cost of [*] for the production of [*]
in a Qualifying Run, which [*] meets
the requirements in this paragraph. Payment for an achieved Milestone 4 will be made within thirty (30) days after agreement by
Steering Committee that this Milestone 4 has been achieved. To satisfy this Milestone 4, (i) the [*] shall
have a chemical purity that meets the Ingredient Specifications, (ii) the [*] shall
have a mass conversion yield of the [*] (on a pure basis) to [*],
and (iii) the final [*] produced from such [*] must
meet an olfactive standard set by Firmenich. In determining whether or not the Target Cost was achieved in this Qualifying Run,
the Parties will use the agreed assumed costs of raw materials and fermentation set forth in the Target Cost Model. Recognition
and payment of this Milestone 4 will impose, commencing January 1, 2017, a cap on the Fully-Burdened Ingredient Manufacturing Costs
of [*] supplied by Amyris to Firmenich at [*].
This cap may be renegotiated by the Parties in the event of extraordinary currency exchange rate fluctuations. 

 

For
purposes of Milestone 3 and Milestone 4, the Ingredient Specifications for [*] delivered
under such milestones, and the timelines and the analytical methods for determining its compliance with the applicable milestone
will be agreed by the Technical Committee in writing prior to the start of the pilot production campaign for [*] at
Amyris’s Brotas facility. 

 

These milestones reflect achievement
of certain technical parameters, such as yield and productivity of Strains, and/or delivery of a specified sample volume of the
Intermediate or Ingredient such that it provides confidence to the Parties that Amyris has sufficiently progressed on the Project
to allow the Parties to envision and plan for commercialization of the applicable Intermediate or Ingredient.”

 

		2.	Section 21.2.1 of the Agreement is hereby amended by deleting such section in its entirety and
replacing it with the following new section 21.2.1:

 

“21.2.1(a) General
Principle. The Parties agree to share Profits from Firmenich’s sale of Intermediates and Ingredients on the basis of
70% of such Profits to Firmenich and 30% of such Profits to Amyris until such time as Firmenich receives fifteen million U.S. dollars
(US$15,000,000) more than Amyris from its share of Profits. After such time, the sharing of Profits will become 50% of such Profits
to each Party. Sharing of Profits will be based solely on the sale of the Intermediates and Ingredients themselves, and not any
Fragrance or Flavor of which the Intermediates or Ingredients comprises. Profits will in all cases be paid within sixty (60) days
after the end of each calendar quarter.

 

[*] Certain
portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.

    
	CONFIDENTIAL	 Page 2 of 5	 

     

    

(b)
       Exception for [*].
Notwithstanding the foregoing in subsection (a), the Parties agree that: 

 

		(1)	the Profits from Firmenich’s sale
of any (i) [*] that is purchased from Amyris during calendar year
2015 or calendar year 2016 or (ii) any Intermediate or Ingredient, including [*] or
[*], produced from [*] that
is purchased from Amyris during calendar year 2015 or calendar year 2016 shall be split [*];

 

		(2)	the Profits from Firmenich’s sale
of any [*] produced from [*] that
is purchased from Amyris on or after January 1, 2017 shall be, and at all times remain, [*];

 

		(3)	the Profits from Firmenich’s sale
of any [*] produced from [*] that
is purchased from Amyris on or after January 1, 2017 shall be, and at all times remain, [*];

 

		(4)	the Profit splits described in clauses
(1), (2), and (3) of this subsection (b) are independent of subsection (a) and will not be amended, changed or otherwise affected
by the shift under subsection (a) to [*]; 

 

		(5)	none of the Profits from Firmenich’s
sale of any [*] or of any Intermediate or Ingredient, including
[*] or [*],
produced from [*] will count toward triggering the [*] split
in subsection (a); and

 

		(6)	For clarity, any Profits from Firmenich’s
sale of any (i) [*] that is purchased from Amyris on or after January
1, 2017 or (ii) Intermediate or Ingredient (excluding [*] and [*])
produced from [*] purchased from Amyris on or after January 1,
2017 shall be subject to the Profit split(s) set forth in subsection (a) above. 

 

In
addition, the Parties agree that, notwithstanding anything to the contrary in this Agreement (including section 3.11), any Firmenich
Non-Project Intellectual Property that is or may be used to produce [*] or
any Intermediate or Ingredient made from [*] (including [*])
will be considered Firmenich Non-Project Royalty-Bearing Intellectual Property, but no royalty payment or other compensation is
or will be due or payable to Firmenich for such use.”

 

		3.	Section 21.3 of the Agreement is hereby amended by deleting such section in its entirety and replacing
it with the following new section 21.3:

 

“21.3Success
Bonus. Amyris shall pay to Firmenich a success bonus (the “Bonus”) for commercializing the Intermediates or Ingredients,
which shall be calculated as set forth in Appendix F. However, the Parties agree that, consistent with section 21.2.1(b)(5), none
of the Profits from Firmenich’s sale of any [*] or of any
Intermediate or Ingredient, including [*], produced from [*]
will be included in the calculation of the first criterion of the “Bonus
Trigger” in such Appendix F.”

 

 

 

[*] Certain
portions denoted with an asterisk have been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions.

    
	CONFIDENTIAL	 Page 3 of 5	 

     

    

Appendix F of the Agreement (i.e.,
Model for Calculation of Bonus) is hereby amended by deleting such appendix in its entirety and replacing it with the new Appendix
F attached hereto as Attachment 1.

 

		4.	Capitalized terms used in this First Amendment shall have the same meaning as defined in the Agreement
unless otherwise defined herein. Except as specifically provided in this First Amendment, the terms and conditions of the Agreement
shall remain in full force and effect, and unchanged. Together, the Agreement and this First Amendment constitute the entire agreement
between the Parties, and supersede any and all prior negotiations, representations, correspondence, understandings and agreements
with respect to the subject matter of this First Amendment. To the extent of any conflict between the Agreement and this First
Amendment, this First Amendment shall supersede and govern solely to the extent of such conflict. This First Amendment may be executed
in counterparts, which together shall constitute one document and be binding on the Parties.

 

IN WITNESS WHEREOF,
and intending to be bound by the provisions hereof, the Parties have caused this First Amendment to be executed personally or by
their duly authorized representatives, to be effective as of the First Amendment Effective Date.

 

	AMYRIS, INC.	 	FIRMENICH SA
	 	 	 	 	 
	Signature:	/s/ Keri Zook	 	Signature:	/s/ Genevieve Berger
	By:	Keri Zook	 	By:	Genevieve Berger
	Title:	V.P., Assistant General Counsel	 	Title:	CHIEF RESEARCH OFFICER
	 	 	 	 	 
	 	 	 	Signature:	/s/ Boet Brinkgreve
	 	 	 	By:	Boet Brinkgreve
	 	 	 	Title:	 PRESIDENT INGREDIENTS & PRESIDENT FIRMENICH CHINA

 

 

 

 

 

    
	CONFIDENTIAL	 Page 4 of 5	 

     

    

Attachment 1

 

 

APPENDIX F

 

MODEL FOR CALCULATION OF BONUS

 

Bonus Calculation

 

Bonus Intent: As Firmenich is solely responsible for
the commercialization of Firmenich Product from the Collaboration, Amyris will pay a one-time bonus to Firmenich, conditional on
achieving certain requirements set forth below, in order to incentivize those efforts.

 

Bonus Schedule:

	Year in Which Bonus Trigger Achieved	One-Time Commercialization  Bonus Payment	 
	Years 1 - 5	[*]	 
	Year 6	[*]	 
	Years 7 onwards	[*]	 

 

Years 1-5: June 1, 2014 through May 31, 2019

Year 6: June 1, 2019 through May 31, 2020

Year 7 onwards: on or after June 1, 2020

 

Bonus Trigger: trigger for the one-time payment of a
commercialization bonus from Amyris to Firmenich is defined as achieving all of the following:

		-	The Parties’ [*] split
is triggered under section 21.2.1(a).

		-	Firmenich is making all Reasonable Efforts to commercialize Firmenich Products from the Collaboration pursuant to Article 2.5,
including but not limited to such activities as conducting customer sampling, marketing and promotion, and providing customer service
to support product sales.

		-	Firmenich has provided a 5-year business plan to the Steering Committee, which will be updated on an annual basis and which
demonstrates their intentions for the growth of Firmenich Product sales commensurate with the market conditions for that product
or products.

 

One-Time Commercialization Bonus Payment 

		-	The Bonus will be paid as a one-time payment from Amyris to Firmenich within 60 days of Firmenich achieving the Bonus Trigger.

		-	If Bonus Trigger is achieved within Year 6, payment will be [*]
on a monthly basis (e.g., if Bonus Trigger is achieved 4 months into Year
6, payment will be [*]).

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

 

	CONFIDENTIAL	Page 5 of 5Exhibit 10.77

 

 

CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

Confidential

 

AMENDMENT #2 

TO THE COLLABORATION AGREEMENT

 

This Amendment #2 to the
Collaboration Agreement (the “Second Amendment”) is entered into on November 23, 2016 (the “Second
Amendment Effective Date”) between Amyris, Inc. and Firmenich
SA.

 

Whereas, the
Parties hereto entered into the Collaboration Agreement on March 13, 2013, which was subsequently amended by Amendment #1 to the
Collaboration Agreement, dated July 1, 2015 (the Collaboration Agreement as amended is called the “Agreement”);

 

Whereas, Amyris
has entered into a collaboration agreement with [*] (“[*]”) to develop certain compounds (“[*]Collaboration Agreement”);
and

 

Whereas, the
Parties wish to further amend the Agreement to 1) define how the Parties have agreed to collaborate in light of the [*]Collaboration
Agreement, by extending the definition of Exclusions, the access, manufacture and supply rights as well as the conditions of sale;
and, 2) transfer the ownership of the Escrowed Materials to Firmenich, and 3) clarify the definition of “repellent”
falling within the F&F Market.

 

Now Therefore,
the Parties hereto agree as follows:

 

		1.	The definition of Exclusions found in Section 1.16 of the Agreement is amended by adding the following
to the Exclusions: “The following ingredients, including intermediates thereof which are collectively referred to as the
“Excluded Ingredients”, are also Exclusions: [*].

 

		2.	The definition of F&F Market found in Section 1.17 of the Agreement is clarified as follows
and the following parenthetical after “repellant” is added: “(an ingredient that induces repulsion or attraction
in any arthropod, pest or other animal and which acts via olfactory or taste receptors and/or the olfactory and taste systems)”.
This clarification of the term and the meaning of repellant will operate with effect from the Effective Date of the Agreement.

 

		3.	The following sentences are added to Section 2.1, General Scope, of the Agreement: “With
regard to the Excluded Ingredients however, if the circumstances in Sections 2.8.6 and 2.8.7 occur with respect to any of the individual
Excluded Ingredients, or if the [*]Collaboration Agreement expires or is terminated for any reason, or Amyris is no longer bound
by the [*] Collaboration Agreement for any other reason, then the Excluded Ingredients will revert back to the Collaboration and
consequently be deemed to be included within the F&F Market under this Agreement.”

 

		4.	The following sections are added as a new Section 2.8:

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

     

    Confidential

    

“Section 2.8, Development of Excluded Ingredients
in Collaboration with [*]. Amyris has the right to enter into an agreement with [*] relating to the research, development,
manufacture, supply and commercialization of the Excluded Ingredients as a Flavor Ingredient subject to the following conditions:

 

		2.8.1.	Firmenich will purchase for its internal use only (and not for re-sale) the Excluded Ingredients
from [*] and/or Amyris under Firmenich’s standard purchasing terms and conditions.

 

		2.8.2.	If the net selling price [*] charges Firmenich for the sale of the Excluded Ingredient is more
than Amyris’ Fully-Burdened Cost for the Excluded Ingredient plus [*], then Amyris will compensate Firmenich for the difference
within thirty (30) days after a request is made by Firmenich. “Fully-Burdened Cost for the Excluded Ingredient” is
based upon the elements and principles used in the agreed cost model for [*] (as shared between the Parties after each production
campaign).

 

		2.8.3.	The Steering Committee will determine according to the decision making process shown in Section
2.6, the Target Cost for the Excluded Ingredients (based on the Target Cost Model). The Steering Committee will also advise upon
the scope of the development of the Excluded Ingredients, guided by the interest to support Amyris to achieve and maintain global
standards of naturalness for flavors.

 

		2.8.4.	If [*] cannot produce the quantities of Excluded Ingredient(s) required by Firmenich, then Amyris
will manufacture or have manufactured the Excluded Ingredient(s) and sell the requested amount of Excluded Ingredient(s) to Firmenich
at Amyris’ Fully-Burdened Cost for the Excluded Ingredient plus [*] regardless of Amyris’ Target Cost for the Excluded
Ingredient(s), but capped at [*].

 

		2.8.5.	The record keeping and auditing provisions in Section 4, Audit Rights, apply to the data and information
provided on the Fully-Burdened Cost for the Excluded Ingredient(s). If Amyris cannot produce the Excluded Ingredient(s) at [*],
the Parties will negotiate a new mark-up percentage in good faith as per the process established in the Collaboration Agreement.

 

		2.8.6.	If [*] or Amyris, as the case may be, cannot achieve a cost of an Excluded Ingredient of [*]. The
occurrence of such an event will be formally confirmed by the Steering Committee.

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 	2	 

    Confidential

    

		2.8.8.	If the Excluded Ingredients are not commercialized by [*] on or before June 28, 2019, being thirty
six (36) months after the signature date of the [*] Collaboration Agreement ([*]), then the Excluded Ingredients will automatically
[*]. The occurrence of such an event will be formally confirmed by the Steering Committee.

 

		2.8.9.	If Amyris or an Amyris Affiliate manufactures and sells an Excluded Ingredient product to [*],
Amyris will pay to Firmenich a royalty of [*].

 

		2.8.10.	Within five (5) business days after the end of each calendar quarter, Firmenich will provide to
Amyris the volumes and price paid by Firmenich for Excluded Ingredient(s) purchased during the same quarter, allowing Amyris to
deduct the volumes sold to Firmenich from its total sales of the Excluded Ingredient and to provide for the calculation of the
royalty amounts.

 

		2.8.11.	Within fifteen (15) business days following the notification by Firmenich of Excluded Ingredient
volumes purchased during the quarter, and for each calendar quarter during which Excluded Ingredient have been sold, Amyris will
provide Firmenich with reports of its Net Sales of Excluded Ingredients.

 

		a.	Each of the foregoing reports will include (for the relevant period) (i) quantities of Excluded
Ingredient sold to Third Parties, (ii) the average selling Price for such sales; (iii) the associated cost (as per cost model described
in Section 2.8.3); and (iv) the royalty amount to be paid to Firmenich.

 

		b.	The audit rights shown in Section 4, Audit Rights, apply to all Amyris records (including financial
and supply records) to allow the verification of payments in accordance with this clause 2.

 

		2.8.12.	Amyris will pay to Firmenich such amounts within sixty (60) days after receipt of the invoice.
Payments will be made in U.S. Dollars by wire transfer to an account designated by Firmenich.

 

		2.8.13.	The [*] Collaboration Agreement contains provisions regarding a change in control, insolvency,
confidentiality and insurance as well as other provisions required to ensure the continued supply of the Excluded Ingredient to
Firmenich. Amyris warrants and undertakes that the [*] Collaboration Agreement and all collaboration with [*] complies strictly
and will comply at all times during the Agreement with the terms and conditions of the Agreement and does not in any way prejudice
Firmenich’s

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 	3	 

    Confidential

    

		2.8.15.	rights and interests, in particular, but not limited to the specific provisions on assignment or
access to Amyris’ Strain Generation Technology and Amyris Collaboration Intellectual Property. As agreed in the Steering
Committee, Amyris shall provide to Firmenich within 30 days of the Second Amendment Effective Date written confirmation of this
non–infringement commitment by Amyris in a separate letter.

 

		2.8.16.	Amyris will ensure that [*] does not communicate externally or issue any press release or similar
public communication about its collaboration with Amyris. Before issuing any press release or similar public communication relating
to the collaboration on any Excluded Ingredient, Amyris will first obtain the prior written consent of Firmenich.

 

		2.8.17.	Amyris will inform Firmenich as soon as reasonably possible if the [*] Collaboration Agreement
expires, is terminated or is amended or if either event described in Sections 2.8.6 and/or 2.8.7 occurs.

 

		2.8.18.	Amyris will provide to Firmenich a redacted copy of the [*] Agreement so that Firmenich can verify
that the required provisions as stated in 2.8.12 are present. The redacted [*] Agreement will be treated as Confidential Information
pursuant to Section 8, Confidentiality.

 

		2.8.19.	Any assignment, outsourcing or sub-contracting by Amyris of the manufacturing or other rights of
the Excluded Ingredients to a third party is conditioned upon the royalty payment obligation (2.8.8), the pricing compensation
(2.8.2) and the procurement obligation (2.8.4) to Firmenich.”

 

		5.	As of the Second Amendment Effective Date, the ownership of all Escrowed Materials relating to
[*] that are in escrow pursuant to the Escrow Agreement dated August 22nd, 2013, between the Parties and the Escrow Agent, (the
“Transferred Materials”) are hereby transferred from Amyris to Firmenich. Amyris shall within fifteen (15) business
days following the Second Amendment Effective Date, take all measures and actions necessary to release the Transferred Materials
from escrow and to deposit them in Firmenich’s name in a deposit account with the Escrow Agent or such other Agent Firmenich
choses. For the avoidance of doubt, Transferred Materials include all technical reports (including strain development history)
describing the work to date under the Work Plan, copies of all supporting manufacturing SOPs and all other material development-related
documentation for each Intermediate and Ingredient developed under its Work Plan.

 

		5.1.	The Parties will request an amendment of the Escrow Agreement’s Release Conditions for the
specific purpose shown above. Amyris will confirm the release instructions according to Exhibit A of the Escrow Agreement.

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 	4	 

    Confidential

    

		5.2.	The Escrow Agreement will remain in place for the deposit of future Strains. For the sake of clarity,
any future Strains developed after the Second Amendment Effective Date will be deposited in escrow in accordance with the terms
of Section 3.4 of the Agreement, Development Strain Escrow.

 

		5.3.	For the sake of clarity, Firmenich will use the Transferred Materials within the limitations of
the Collaboration Agreement including, but not limited to, Sections 6.3 (Firmenich’s Representations and Warranties), 8 (Confidentiality),
and 9 (Exclusivity).

 

		6.	Amyris promises to pay or transfer to Firmenich the following:

 

		6.1.	The transfer of the ownership of the Transferred Material represents a value of [*] to Firmenich;

 

		6.2.	Amyris hereby gives Firmenich a credit of [*] which is or will be applied to an order of [*] that
has already been received by Amyris;

 

		6.3.	Amyris will sell to Firmenich an additional [*] pursuant to the Supply Agreement between the Parties
(which represents a value of [*]). The sales schedule has been mutually agreed upon by the Parties ;

 

		6.4.	Amyris will provide training to Firmenich employees at Amyris’ Brotas plant, representing
a value of [*]. This corresponds to [*], to be allocated by Amyris for such training. The training plan will be established between
the Parties after the Second Amendment Effective Date, no later than January 2017. Amyris will not reimburse Firmenich for travel,
hotel or other accommodation expenses incurred by Firmenich employees in attending such training.

 

		7.	Without affecting any other right or remedy available, Firmenich may terminate this Second Amendment
and the Agreement (Section 20.2/ 20.4.3 of the Agreement) with immediate effect by giving written notice to Amyris (or at such
other date as specified in the notice) if Amyris commits a breach of any term or condition of this Second Amendment and such breach
has not been remediated within 30 days after written notice of such breach by Firmenich.

 

		8.	Capitalized terms used in this Second Amendment have the meaning defined in the Agreement unless
otherwise defined herein. Except as specifically provided in this Second Amendment, the terms and conditions of the Agreement shall
remain in full force and effect, and unchanged. Together, the Collaboration Agreement, the First Amendment and this Second Amendment
constitute the entire agreement between the Parties, and supersede any and all prior negotiations, representations, correspondence,
understandings and agreements

 

[*] Certain portions denoted with an asterisk have been omitted
and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions.

 

    	 	5	 

    Confidential

    

with respect to the subject matter of the Agreement,
the First Amendment and the Second Amendment. This Second Amendment may be executed in counterparts, which together shall constitute
one document and be binding on the Parties. Unless otherwise explicitly noted, all of the amendments shown in this Second Amendment
are effective as of the Second Amendment Effective Date.

 

 

 

 

 

In Witness Hereof,
the Parties executed this Agreement as of the Second Amendment Effective Date.

 

 

 

	Amyris, Inc.	 	Firmenich SA
	 	 	 
	Signature 	/s/ John Melo	 	Signature	/s/ Boet  Brinkgreve
	By :	John Melo	 	By :	Boet  Brinkgreve
	Title :	CEO	 	Title :	President Ing & China
	 	 	 	 	 
	 	 	 	Signature	/s/ C. Dean
	 	 	 	By :	C. Dean
	 	 	 	Title :	VP R&D   02 Dec 2016

 

 

 

 

 

 

 

 

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]